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South African statistics on cigarette smoking suggest 
that there are grounds for some celebration on how 
rapidly consumption has fallen since the institution of 
anti-smoking policies started roughly 20 years ago. [1] 
As with other countries, tax policies that increased 
the cost of cigarettes will have played the greatest role in the reduction 
in smoking. These policies have also resulted in strong economic 
benefits, saving up to 1.5 million lives and put over US$12.5 billion 
into the economy.[2] The authors of this paper were both very involved 
in achieving these policies: in 1993, Derek Yach hosted the first 
national meeting to brief the African National Congress on the need 
for stronger taxes to address tobacco use, and in that meeting David 
Sweanor outlined the success taxes had already achieved in his home 
country of Canada.
The level of continuing cigarette consumption despite all 
interventions to date, and the unintended consequences of these 
price policies (including smuggling and economic disadvantage 
of those unable to quit smoking), argues powerfully for a look at 
new breakthrough interventions. Rather than simply putting more 
resources into achieving diminishing returns on long established 
areas of intervention we need to actively look for the ‘next big thing’ 
in dealing with the health toll caused by smoking.
One of the most striking realities about tobacco control activities 
over the past two decades is that they fail to address the product 
itself. Instead, measures to date have focused on such things as 
where cigarettes can be sold, to whom, the price, where they can 
be used, what warnings must be displayed, and disclosure of toxic 
constituents. This oversight is rather extraordinary since we have 
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known for decades that ‘smokers smoke for the nicotine but die from 
the smoke’, a point now reiterated very strongly by the Royal College 
of Physicians and others who call for harm-reduction principles to 
be applied to tobacco policy.[3,4] This failure to address the delivery 
system is analogous to trying to reduce traffic fatalities while ignoring 
the modifiable risks in automobiles themselves.
We also know that a very significant proportion of smokers can 
obtain nicotine in ways that do not require the incredibly dangerous 
lung inhalation of the products of combustion; the process that 
causes them to ‘die from the smoke’ while they seek the nicotine they 
need or want. The Swedish experience with smokeless ‘snus’ (oral 
snuff) is proof-of-concept that disease risk can be massively reduced 
through use of a different delivery system.[5] The very rapidly growing 
global demand for electronic cigarettes (e-cigarettes) reinforces this 
message with what appears to be a far more acceptable product for 
many smokers, and even the presence of long-term users of nicotine 
replacement therapy (who use the products for well over a decade), 
shows the viability of vastly less hazardous alternatives to obtaining 
nicotine via smoking cigarettes.
In effect, what anti-smoking policies have done to date is to 
motivate smokers to want to quit, while doing exceedingly little to 
facilitate the sought behaviour change. To be maximally effective, 
policy measures must combine motivation for behaviour change with 
pragmatic facilitation. 
The opportunity this presents for public health is hard to overstate. 
Sitas et al.[6] recently indicated that tobacco deaths will remain a 
major contributor to the burden of disease in South Africa (SA) and 
in fact increase over the next few decades unless stronger action is 
taken. And, what is true for SA is also true globally.
There has been outstanding success in getting smokers to the 
point that they wish to quit, and we need to listen to them rather 
than continue to simply pile on dire messages, higher taxes and 
social isolation for those who still smoke. Smokers are clearly looking 
for viable options, while few are being offered. This failure to give 
acceptable alternatives to smokers is particularly hard to justify when 
we know, for instance, that genetic factors play a huge role in nicotine 
dependence and the ability to quit and that a great deal of smoking 
can be explained by self-medication with nicotine to treat a wide 
range of conditions.[7,8]
Further, we know that financial incentives can yield higher 
quit rates after 12 months than most other carefully evaluated 
interventions but that the best results remain quit rates of only 14% 
after a year.[9] To simply give a message of abstinence is as ineffective 
as it is unethical. It is far easier to move consumers off smoking than 
to move them off nicotine, and doing so delivers nearly all of the 
health benefits of total cessation.[10]
We also know that in the absence of giving smokers good 
alternatives, they will not be idle. Cognitive dissonance will drive 
them to belittle their actual personal risks and to discount our 
package warnings.[11] Taxes will drive them to illicit supplies. Smoke-
free policies will be seen as a ‘bonding experience’.
We have a chance to seize on the current market disruption being 
caused by e-cigarettes and to ride, rather than fight, the wave of 
interest among smokers. This wave shows strong signs of building 
as technological progress makes such products ever more acceptable 
to ever larger numbers of current smokers, and at prices increasingly 
cheaper than cigarettes. In fact, a leading Wall Street tobacco stock 
analyst forecasts that these products are well on their way to outselling 
cigarettes if we simply avoid measures that would protect combustion 
cigarettes from the onslaught of disruptive technology.[12] We could 
well be en route to a huge global public health breakthrough on 
smoking-caused disease through a self-financing move by smokers 
themselves, one that requires little, if any, expenditure of government 
resources. As with other recent introductions of new technology 
the marketplace transition could be extremely rapid. This transition 
can be aided by policy measures, such as ensuring that taxes keep 
cigarettes more expensive than less hazardous alternatives, as cross-
elasticity has been shown to be a powerful force for moving smokers 
to alternative products.[13]
Are there risks as we embrace measures that fundamentally 
challenge the near-monopoly on nicotine maintenance currently 
held by the cigarette oligopoly? Certainly there are. They are 
well summarised in recent reviews.[14] But these risks must be 
seen in relation to the risks of inaction (or counterproductive 
actions), which will inevitably mean the perpetuation of the 
cigarette epidemic. Would we hesitate to offer brewed tea and 
other caffeinated beverages to people who currently were only 
aware that caffeine could be obtained through the smoking of tea 
leaves? The biggest public health risk when simultaneously faced 
with an epidemic and the ability to control it is to fail to grasp the 
opportunity. 
We can still strive for complete nicotine cessation (and products 
less addictive than combustion cigarettes will actually assist such 
a goal rather than impede it), but we are currently presented with 
the very real prospect of massively reducing the individual and 
population risks of smoking by something in the range of two orders 
of magnitude. If we seize the opportunity for this new breakthrough, 
SA can once again be on the forefront of cutting-edge health policy. 
For those of us personally fortunate enough to be alive and healthy in 
another 20 years, we could be looking at a world where the smoking 
of cigarettes seems as much an anachronism as trepanning. We will 
have finally finished the work we started 20 years ago. 
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